Structure Therapeutics (GPCR) announced that it will present topline results from its pivotal ACCESS clinical program evaluating Aleniglipron for the treatment of obesity on December 8, 2025.
ACCESS is a phase 2 program, which includes two studies - ACCESS and ACCESS II.
ACCESS is a Phase 2b randomized placebo-controlled, 36-week study that enrolled approximately 220 adults with obesity, or overweight with at least one weight-related comorbidity, evaluating doses up to 120 mg of Aleniglipron with a four-week titration schedule. An Open Label Extension of the ACCESS study is ongoing.
ACCESS II is a Phase 2 randomized placebo-controlled study that enrolled approximately 80 adults with obesity, or overweight with at least one weight-related comorbidity, evaluating higher doses of aleniglipron (180 mg and 240 mg) with a four-week titration schedule. Following the initial 36-week evaluation, patients continue in the study to 44 weeks, which allows for collection of an additional eight weeks of double-blinded safety, tolerability, and efficacy data.
Aleniglipron is a once-daily oral small molecule selective GLP-1 receptor agonist being developed to provide a more convenient alternative to injectable GLP-1 therapies for obesity and overweight.
The company ended September 30, 2025, with a cash balance of $799.0 million, expected to fund operations and clinical milestones through at least 2027.
GPCR closed Friday's trading session at $34.56, up 5.21%, and rose a further 2.17% to $35.31 in overnight trading. Over the past 12 months, the stock has traded between $13.22 and $40.29.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.